Zipalertinib for lung cancer with EGFR exon 20 mutations
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 trial tests zipalertinib (a targeted pill) in people with advanced non-small cell lung cancer (NSCLC) that has specific EGFR mutations, especially “exon 20 insertions.” It may help shrink tumors or slow cancer growth, including in some people with brain metastases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can sign the consent form
- Your lung cancer is confirmed on pathology as advanced or metastatic NSCLC
- Your tumor test shows an EGFR mutation that the study is looking for (often EGFR exon 20 insertions)
- Your cancer has measurable disease and you can provide stored tumor tissue for testing
- You are well enough to participate (ECOG performance status 0 or 1) and your blood/heart/liver/kidney tests are adequate
- If you have brain metastases, they must be stable after treatment, with no recent worsening and stable seizure/steroid medicines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial gives access to an investigational drug called zipalertinib for people with a specific type of advanced lung cancer (EGFR exon 20 insertion) who have already tried chemotherapy. The goal is to see if the drug can help control the cancer when other treatments have stopped working.
This study tests whether taking zipalertinib after lung cancer surgery can help prevent the cancer from coming back in people whose tumors have uncommon EGFR gene changes. It is a pill taken daily after recovery from surgery.
This trial tests zipalertinib, a targeted pill for people with non-small cell lung cancer that has an atypical EGFR gene change. It is given after standard treatment like surgery or radiation to help prevent the cancer from coming back.
This trial tests a new targeted pill (zipalertinib) combined with standard chemotherapy (carboplatin and pemetrexed) before surgery for early-stage lung cancer with specific EGFR mutations. It aims to shrink the tumor and potentially improve outcomes after surgery.
This trial is testing a new targeted pill for people with EGFR-positive non-small cell lung cancer. It's designed for those whose cancer has grown after other treatments, and it works by blocking a specific protein that helps the cancer grow.
This study tests a new pill called PLB1004 for people whose lung cancer has a specific EGFR mutation (exon 20 insertion). It is for those who have not yet had any treatment for their advanced cancer.
Hear when a new Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.